The clinical course of follicular lymphoma

Follicular lymphoma serves as a paradigm for the other subtypes of non-Hodgkin's lymphoma previously collectively known as ‘indolent’ or ‘low-grade’. As such, its clinical course (that is, the natural history as influenced by conventional therapy) can act as a useful baseline against which the...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical haematology 2005-03, Vol.18 (1), p.1-10
Main Authors: Rohatiner, Ama Z.S., Lister, T. Andrew
Format: Article
Language:English
Subjects:
Cell Transformation, Neoplastic
clinical course
conventional treatment
Disease Progression
follicular lymphoma
Humans
Lymphoma, Follicular - mortality
Lymphoma, Follicular - pathology
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - pathology
Prognosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Follicular lymphoma serves as a paradigm for the other subtypes of non-Hodgkin's lymphoma previously collectively known as ‘indolent’ or ‘low-grade’. As such, its clinical course (that is, the natural history as influenced by conventional therapy) can act as a useful baseline against which the efficacy of new approaches may be assessed. The illness is characterised by repeated responsiveness to treatment but typically this is transient and incomplete. Death occurs at a median of 9–10 years after diagnosis, generally as a consequence of resistant disease, transformation to diffuse large B cell pathology or as a result of side effects of therapy. It has been demonstrated that there is no survival advantage associated with starting treatment prior to there being a clinical need to do so. It is hoped that the advent of new treatment modalities will alter the inexorable pattern of recurrence.
ISSN:1521-6926
1532-1924
DOI:10.1016/j.beha.2004.06.002